Clinical Trials
Search Form
Disease Site | Trial | Trial Description | Trial Status Sort descending | Lead Cooperative Group |
---|---|---|---|---|
Endometrial | AtTEnd/ENGOT-EN7 |
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer |
Closed to Recruitment | MaNGO |
Endometrial | ENGOT-EN11/GOG-3053/KEYNOTE-B21 |
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus placebo in combination with adjuvant chemotherapy with or without radiotherapy for the treatment of newly diagnosed High-Risk Endometrial Cancer after surgery with curative Intent |
Closed to Recruitment | BGOG |
Endometrial | STATEC |
A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer |
Completed | NCRI |
Endometrial | KGOG 2015 |
Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer |
Completed | KGOG |
Endometrial | TOTEM |
Trial between Two Follow up Regimens with Different Intensity in Endometrial Cancer Treated Patients |
Completed | MaNGO |
Fallopian Tube & Ovarian | VIP |
Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
Recruiting | GCGS |
Gestational Trophoblastic Neoplasia | GOG 0275 |
Dactinomycin or Methotrexate in Treating Patients with Low Risk Gestational Trophoblastic Neoplasia |
Recruiting | GOG-F |
Ovarian | ENGOT-OV62/ NOGGO OV 53/ N-Plus |
A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high grade ovarian cancer patientS in first line therapy |
Pending | NOGGO |
Ovarian | SALVOVAR |
A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery |
Pending | GINECO |
Ovarian | ENGOT-ov51/NItCHE/MITO33 |
Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer |
Recruiting | MITO |
Ovarian | SUNNY/SGOG OV4B |
A Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer(SUNNY) |
Recruiting | SGOG |
Ovarian | ENGOT-ov72/ROSELLA |
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
Recruiting | MITO |
Ovarian | ENGOT-ov54/Swiss-GO-2/MATAO |
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial Including LOGOS (Low Grade Ovarian Cancer Sub-study). |
Recruiting | Swiss-GO |
Ovarian | GLORIOSA |
Randomized, multicenter, open-label, phase 3 study of mirvetuximab |
Recruiting | MITO |
Ovarian | AGO-OVAR 28 |
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane based Chemotherapy in Advanced Ovarian Cancer |
Recruiting | AGO |
Ovarian | CHRONO |
Retarded surgery following neoadjuvant chemotherapy in advanced ovarian cancer |
Recruiting | GINECO |
Ovarian | NIRVANA-1 |
A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery |
Recruiting | GINECO |
Ovarian | ENGOT-ov56-NSGO-CTU/DOVACC |
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer |
Recruiting | NSGO-CTU |
Ovarian | TEDOVA |
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC |
Recruiting | GINECO |
Ovarian | NSGO-CTU/HERO |
Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study |
Recruiting | NSGO-CTU |